RadnostixINIS +2.73% OCF Margin % is -3.03% as of Mar. 2026. The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Radnostix ranks worse than 62.15% on this metric.
The historical rank and industry rank for Radnostix's OCF Margin % or its related term are showing as below:
INIS'
s OCF Margin % Range Over the Past 10 Years
Min: -13.4 Med: 0.17 Max: 12.28
Current: 4.54
During the past 13 years, the highest OCF Margin % of Radnostix was 12.28%. The lowest was -13.40%. And the median was 0.17%.
INIS's OCF Margin % is ranked worse than 62.15% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs INIS: 4.54
Radnostix OCF Margin % Related Terms
Radnostix OCF Margin % Historical Data
* Premium members only.
The historical data trend for Radnostix's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radnostix OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Radnostix's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Radnostix's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radnostix (INIS) has a OCF Margin % of -3.03% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Radnostix and its competitors. According to the industry distribution chart, Radnostix ranks #596 out of 959 companies in the Drug Manufacturers industry, placing it in the top 62.1%.
Is Radnostix's OCF Margin % too high?
Radnostix's current OCF Margin % is -3.03%. Based on the distribution chart, Radnostix ranks #596 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Radnostix's OCF Margin % compare to TLPH and IXHL?
According to the Drug Manufacturers industry distribution chart, Radnostix ranks #596 out of 959 companies for OCF Margin %. This places Radnostix in the lower half of its industry. The industry median OCF Margin % is 9.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Radnostix and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radnostix's current OCF Margin % is -3.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 43.8% above its estimated fair value. The current OCF Margin % is -3.03%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Radnostix (INIS), the current OCF Margin % is -3.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INIS has been successfully added to your 